#1 Clinical Trials Search in Europe

Human Igg1 Kappa Monoclonal Antibody Against Tigit

This article summarizes clinical trials investigating the use of Human IgG1 Kappa Monoclonal Antibody Against TIGIT, a novel immunotherapy drug, in treating various types of cancer. The trials aim to evaluate the safety, efficacy, and potential combinations of this antibody with other cancer treatments. The studies focus on patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and melanoma.

Table of Contents

What is HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT?

HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT is an investigational immunotherapy drug being developed to treat various types of cancer[1]. This medication is also known by its sponsor product code GSK4428859 and is being developed by GlaxoSmithKline[2].

To break down the name:

  • Human IgG1: This indicates it’s a human antibody of the IgG1 subclass, which is a type of protein used by the immune system to neutralize threats.
  • Kappa: Refers to one of two types of light chains in the antibody structure.
  • Monoclonal Antibody: This means it’s a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells.
  • Against TIGIT: TIGIT (T cell immunoreceptor with Ig and ITIM domains) is the specific target of this antibody. TIGIT is a protein found on some immune cells that can suppress the immune system’s ability to fight cancer.

How Does It Work?

This drug works by targeting and blocking TIGIT, a protein found on certain immune cells. TIGIT normally acts as a “brake” on the immune system, preventing it from attacking too aggressively. However, some cancers can exploit this brake to avoid being destroyed by immune cells[1].

By blocking TIGIT, this antibody essentially “releases the brake” on the immune system, allowing it to recognize and attack cancer cells more effectively. This approach is part of a broader category of treatments called immune checkpoint inhibitors, which have shown significant promise in treating various types of cancer.

What Conditions Does It Treat?

Based on the ongoing clinical trials, this drug is being investigated for treating several types of advanced or metastatic cancers, including:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer[2].
  • Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the mouth, nose, and throat[1].
  • Other Advanced Solid Tumors: The drug is also being tested on various other types of solid tumors that have advanced or spread[3].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of this drug:

  • A Phase 2 study combining this drug with dostarlimab for patients with recurrent or metastatic head and neck cancer[1].
  • A Phase 3 study comparing this drug (called belrestotug in this trial) plus dostarlimab to pembrolizumab in patients with previously untreated, advanced non-small cell lung cancer[2].
  • A Phase 2 platform study evaluating various combinations of this drug with other immunotherapies for patients with advanced non-small cell lung cancer[4].
  • A Phase 1/2 study investigating this drug in combination with other therapies for patients with various advanced solid tumors[3].

How Is It Administered?

This medication is given as an intravenous infusion, which means it’s delivered directly into your bloodstream through a vein[1]. The exact dosage and frequency of administration may vary depending on the specific clinical trial and the condition being treated.

Potential Side Effects

As this drug is still in clinical trials, the full range of potential side effects is not yet known. However, based on similar immunotherapy drugs, some possible side effects may include:

  • Fatigue
  • Nausea
  • Decreased appetite
  • Skin rash
  • Diarrhea
  • Immune-related side effects affecting various organs

It’s important to note that not everyone experiences side effects, and they can vary from person to person. Your healthcare team will monitor you closely for any adverse reactions during treatment[2].

Future Research and Potential

The development of HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT represents an exciting advancement in cancer immunotherapy. As research continues, scientists hope to better understand which patients are most likely to benefit from this treatment and how it can be combined with other therapies for maximum effectiveness[3].

While the results of ongoing clinical trials are eagerly awaited, it’s important to remember that this drug is still investigational. Patients interested in this treatment should discuss their options with their oncologist and consider participating in clinical trials if appropriate.

Trial Phase Cancer Types Combination Therapies Primary Objectives
Phase 1/2 Advanced solid tumors, NSCLC, HNSCC, Melanoma Dostarlimab, Pembrolizumab, Inupadenant, Standard chemotherapy Safety, tolerability, recommended Phase 2 dose, antitumor activity
Phase 2 Recurrent/Metastatic HNSCC Dostarlimab Antitumor activity compared to dostarlimab monotherapy
Phase 3 Advanced/Metastatic NSCLC Dostarlimab, Pembrolizumab Efficacy compared to pembrolizumab plus placebo

FAQ

  • What is Human IgG1 Kappa Monoclonal Antibody Against TIGIT? Human IgG1 Kappa Monoclonal Antibody Against TIGIT is an immunotherapy drug that targets the TIGIT protein, which is involved in regulating the immune system's response to cancer cells. By blocking TIGIT, this antibody aims to enhance the immune system's ability to fight cancer.
  • What types of cancer are being studied with this antibody? The clinical trials are investigating the use of this antibody in various advanced solid tumors, with a focus on non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and melanoma.
  • How is this antibody being combined with other treatments? The trials are exploring combinations of the Human IgG1 Kappa Monoclonal Antibody Against TIGIT with other immunotherapy drugs like dostarlimab, pembrolizumab, and inupadenant, as well as standard chemotherapy regimens.
  • What are the main goals of these clinical trials? The primary objectives of these trials include evaluating the safety and tolerability of the antibody, determining the recommended Phase 2 dose, assessing its antitumor activity, and studying its efficacy in combination with other cancer treatments.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary between trials but generally include adult patients with advanced or metastatic solid tumors who have not responded to standard treatments or have specific biomarkers. Patients must also meet certain health criteria and have measurable disease.

Ongoing Clinical Trials on Human Igg1 Kappa Monoclonal Antibody Against Tigit

  • Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Finland France Germany Greece Hungary +6

  • Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Spain

  • Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Finland France Germany Greece Hungary +5

  • Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Estonia Finland +14

Glossary

  • TIGIT: T cell immunoreceptor with Ig and ITIM domains, a protein involved in immune system regulation that can be targeted by cancer immunotherapies.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to detect or treat various diseases, including some types of cancer.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
  • Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the moist surfaces inside the head and neck, such as the mouth, nose, and throat.
  • Melanoma: A type of skin cancer that develops from the pigment-producing cells known as melanocytes. It can also occur in the eyes and, rarely, inside the body.
  • PD-L1: Programmed Death-Ligand 1, a protein that plays a role in suppressing the immune system. Some cancer cells express high levels of PD-L1 to evade immune detection.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment based on changes in tumor size.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose in clinical trials.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/study-of-immunotherapy-combinations-with-dostarlimab-for-patients-with-recurrent-metastatic-pd-l1-positive-head-and-neck-cancer/
  2. http://clinicaltrials.eu/trial/study-of-belrestotug-and-dostarlimab-for-patients-with-untreated-advanced-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-eos884448-dostarlimab-and-inupadenant-for-patients-with-advanced-solid-tumors/
  4. http://clinicaltrials.eu/trial/study-of-immunotherapy-combinations-with-gsk4428859-dostarlimab-and-gsk6097608-for-patients-with-advanced-non-small-cell-lung-cancer/